Frost & Sullivan awards SULLIVAN China the '2026 Frost & Sullivan Global CRDMO Annual Company Award'.

On October 20, 2026, Frost & Sullivan (hereafter referred to as "Frost & Sullivan") announced that, based on its research and assessment of the CRDMO industry and the global pharmaceutical R&D market, it had awarded WuXi AppTec the "2026 Global CRDMO Company of the Year" award, recognizing its performance in enabling innovation, operational excellence, and customer value. This marks the tenth consecutive year that WuXi AppTec has received the Frost & Sullivan Best Practice Recognition.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. WuXi AppTec excelled in both: its integrated CRDMO model offers broad capabilities, global manufacturing capacity, and quality management across the full drug development cycle, supported by a network across Asia, Europe, and North America that maintains flexibility and operational resilience.Its integrated CRDMO model covers the entire new drug development process, from early discovery to commercial production, providing clients with services spanning the entire drug development lifecycle. Additionally, WuXi AppTec’s global capacity layout, robust operational performance, and ability to handle increasingly complex new molecular types fully reflect the company’s differentiation advantages.

"WuXi AppTec stands out in the industry by continuously meeting its customers’ evolving innovation needs," said Unmesh Lal, Vice President, Healthcare and Life Sciences at Frost & Sullivan. "As a trusted partner in the global biopharmaceutical innovation space, WuXi AppTec is always committed to helping its customers succeed."

"We are honored to have once again received Frost & Sullivan’s recognition; it is a confirmation of our ongoing ability to create value for customers." Dr. Ge Li, Chairman and CEO of WuXi AppTec, stated. "As a dedicated enabler of the pharmaceutical industry, we will continue to focus on our CRDMO core strategy, helping global customers accelerate the development of innovative therapies and benefit patients worldwide."

Innovation is at the core of WuXi AppTec’s growth strategy. The company therefore continues to invest in the development and manufacturing capabilities for emerging therapeutic modalities and advanced technologies, including oligonucleotides, peptides, and related conjugated medicines. These investments enhance lead candidate optimization and accelerate development efficiency.

WuXi AppTec’s operational excellence also manifests in quality and regulatory compliance. In 2025 alone, the company completed 741 regulatory inspections and customer audits with zero critical findings. Its One Global Quality System supports standardized governance and quality practices across operating locations, while integrated project management enables teams to effectively address complex technical and regulatory challenges.

Every year, Frost & Sullivan awards the "Global Company of the Year Recognition" to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market position, customer value, and competitive strength. The recognition highlights forward-thinking organizations that are shaping their industries through innovation and growth excellence.